GRT Capital Partners L.L.C. decreased its position in Core Laboratories N.V. (NYSE:CLB) by 22.1% during the fourth quarter, Holdings Channel reports. The firm owned 6,358 shares of the company’s stock after selling 1,807 shares during the period. GRT Capital Partners L.L.C.’s holdings in Core Laboratories N.V. were worth $763,000 at the end of the most recent quarter.
A number of other institutional investors have also recently added to or reduced their stakes in CLB. Bbva Compass Bancshares Inc. increased its position in Core Laboratories N.V. by 31.7% in the second quarter. Bbva Compass Bancshares Inc. now owns 5,847 shares of the company’s stock worth $725,000 after buying an additional 1,409 shares during the period. Ngam Advisors L.P. increased its stake in Core Laboratories N.V. by 11.0% in the second quarter. Ngam Advisors L.P. now owns 103,877 shares of the company’s stock valued at $12,869,000 after buying an additional 10,274 shares during the last quarter. Evercore Wealth Management LLC increased its stake in Core Laboratories N.V. by 1.4% in the second quarter. Evercore Wealth Management LLC now owns 226,717 shares of the company’s stock valued at $28,088,000 after buying an additional 3,062 shares during the last quarter. WCM Investment Management CA increased its stake in Core Laboratories N.V. by 5.3% in the second quarter. WCM Investment Management CA now owns 3,588,166 shares of the company’s stock valued at $444,538,000 after buying an additional 181,958 shares during the last quarter. Finally, Sustainable Growth Advisers LP increased its stake in Core Laboratories N.V. by 17.2% in the second quarter. Sustainable Growth Advisers LP now owns 1,136,488 shares of the company’s stock valued at $140,799,000 after buying an additional 166,978 shares during the last quarter.
Shares of Core Laboratories N.V. (NYSE:CLB) traded down 0.115% on Tuesday, hitting $116.755. The company had a trading volume of 163,054 shares. Core Laboratories N.V. has a 1-year low of $96.30 and a 1-year high of $135.49. The company has a 50 day moving average price of $120.18 and a 200 day moving average price of $113.43. The firm has a market capitalization of $5.18 billion, a price-to-earnings ratio of 79.969 and a beta of 1.55.
Core Laboratories N.V. (NYSE:CLB) last issued its earnings results on Wednesday, January 25th. The company reported $0.41 earnings per share for the quarter, meeting the consensus estimate of $0.41. The company earned $149.54 million during the quarter, compared to analysts’ expectations of $145.78 million. Core Laboratories N.V. had a return on equity of 65.65% and a net margin of 10.74%. Core Laboratories N.V.’s quarterly revenue was down 18.2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.65 EPS. On average, equities analysts forecast that Core Laboratories N.V. will post $2.09 earnings per share for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, February 17th. Investors of record on Friday, January 20th will be issued a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 1.88%. The ex-dividend date is Wednesday, January 18th. Core Laboratories N.V.’s dividend payout ratio is presently 150.68%.
“GRT Capital Partners L.L.C. Sells 1,807 Shares of Core Laboratories N.V. (CLB)” was originally published by sleekmoney and is the sole property of of sleekmoney. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright and trademark laws. The legal version of this piece can be read at http://sleekmoney.com/grt-capital-partners-l-l-c-sells-1807-shares-of-core-laboratories-n-v-clb/1660636.html.
Several equities research analysts have recently commented on the company. Zacks Investment Research downgraded Core Laboratories N.V. from a “buy” rating to a “hold” rating in a report on Monday, January 30th. Stephens downgraded Core Laboratories N.V. from an “equal weight” rating to a “sell” rating and set a $91.00 price objective for the company. in a report on Wednesday, December 7th. Guggenheim downgraded Core Laboratories N.V. from a “buy” rating to a “neutral” rating in a report on Tuesday, December 6th. Finally, Cowen and Company reissued a “market perform” rating and issued a $105.00 price objective on shares of Core Laboratories N.V. in a report on Saturday, October 22nd. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and four have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $124.92.
About Core Laboratories N.V.
Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.
Want to see what other hedge funds are holding CLB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Core Laboratories N.V. (NYSE:CLB).
This story was originally published by sleekmoney (http://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://sleekmoney.com/grt-capital-partners-l-l-c-sells-1807-shares-of-core-laboratories-n-v-clb/1660636.html
Receive News & Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related companies with MarketBeat.com's FREE daily email newsletter.